Everyone shorting the $ZEC "head and shoulders" pattern isn't looking at the volume pane. Massive green volume surging on the right shoulder completely invalidates the bearish thesis. That’s accumulation, not a breakdown.

1) zcash:native zcash:native / $BTC breakout into perspective: A monthly close above that 2020 level implies that buying ZEC over the last 6 years has actually outperformed holding BTC. 🤯 For over half a decade, the ratio punished anyone who held through the downtrend. This breakout means the tide has turned, and alpha is officially flowing back into Zcash

$ZEC / $BTC Macro Update: • Years of downtrend broken with massive volume expansion • Monthly candle on track to close above the pivotal 2020 yearly close level • MA(9) and MA(20) crossed bullishly, pushing price above the MA(200) • RSI (14) firmly in bullish territory above 70, confirming real strength. One of the cleanest macro accumulation-to-markup phases you will see on a major alt/BTC ratio right now.

Coinbase spending $25M in USDC just to burn an NFT and force Cobie to do 8 episodes of a podcast is wild—but the $375M total package to acquire Echo is where shareholders should really look closer.  $25M for a podcast revival with zero sponsorship rights, where the hosts can literally call the CEO an idiot on air, breaks down to over $3.1M per episode. Great for crypto culture; terrible for capital efficiency and $COIN shareholder value

$ZEC is quietly showing some of the strongest relative strength in the entire market right now. We are officially looking at a massive 7-year structural breakout on the ZEC/BTC chart. Multi-year accumulation is wrapping up and the rotation into privacy scarcity is accelerating. Don't sleep on the math.

zcash:native privacy is inevitable. Do not get shaken out by the day to day price action. Think in years

Don't sleep on what the Lilly/Verve data just proved for the whole gene editing space. 1️⃣ In vivo editing works safely in humans. 2️⃣ Single-dose LNP liver delivery is highly durable. 3️⃣ Big Pharma is aggressively validating "one-and-done" cures. Lilly spending billions here means every major competitor now needs an advanced editing asset. My top high-conviction play is $PRME. Prime Editing is a generation ahead of standard CRISPR, and their liver pipeline hits clinical entry this year

Insiders sell for a million reasons, but they only buy for one. 🧠 A Form 4 just dropped showing $HIMS Director David B. Wells bought 48,400 shares on the open market yesterday at an average of $24.23. That’s a cool $1.17M statement, increasing his direct position by 27.5%

Long $PRME, Massive institutional proof of work for the entire in vivo gene-editing landscape. Big pharma is proving that "one-and-done" curative medicine isn't science fiction—it's actively clearing clinical bars. Lilly's VERVE-102 data shows a staggering 62% reduction in LDL .

Is it a coincidence zcash:native. I think it’s time for June and time for ZEC to break prior year highs here.

Bullish rotations into $CRCL and $TAN

Why I'm bullish on $LPTH : • Q3 Revenue up 109% YoY ($19.1M) • Record backlog of $110.6M (up ~196%) • Proprietary BlackDiamond glass scale outmaneuvering Germanium supply constraints.

$cryptosummer $CRCL zcash:native

Stocks rotate into solar $TAN and crypto $CRCL zcash:native this summer.